Bevacizumab Plus Erlotinib Combination Therapy for Advanced Hereditary Leiomyomatosis and Renal Cell Carcinoma-Associated Renal Cell Carcinoma: A Multicenter Retrospective Analysis in Korean Patients

PURPOSE: Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) is a rare genetic syndrome resulting from germline mutations in fumarate hydratase. The combination of bevacizumab plus erlotinib showed promising interim results for HLRCC-associated RCC. Based on these results, we analyzed the out...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Res Treat
Main Authors: Choi, Yeonjoo, Keam, Bhumsuk, Kim, Miso, Yoon, Shinkyo, Kim, Dalyong, Choi, Jong Gwon, Seo, Ja Young, Park, Inkeun, Lee, Jae Lyun
Formato: Artigo
Idioma:Inglês
Publicado em: Korean Cancer Association 2019
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6790829/
https://ncbi.nlm.nih.gov/pubmed/30913859
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4143/crt.2019.086
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados